SCYNEXIS completed the transfer of the BREXAFEMME (ibrexafungerp) New Drug Application to GlaxoSmithKline, allowing GSK to begin regulatory interactions with the FDA for a U.S. relaunch of the drug for vulvovaginal candidiasis and refractory cases. The transfer finalizes a partnership that began with an exclusive license in March 2023, which included a $90 million upfront payment and the potential for future milestone payments and royalties.
The deal positions SCYNEXIS to receive up to $145.5 million in annual net‑sales milestones and royalties once BREXAFEMME is commercialized. The company already secured $24.8 million from GSK in Q4 2025 following the resolution of a disagreement over the Phase 3 MARIO study, and the new transfer is expected to extend SCYNEXIS’s cash runway beyond two years, providing a non‑dilutive source of capital to fund its pipeline.
SCYNEXIS’s Q3 2025 financial results showed a net loss of $8.6 million on cash reserves of $37.9 million. The milestone payments from GSK are projected to offset the loss and support ongoing development of SCY‑247, a second‑generation fungicidal candidate for invasive fungal infections that is slated to report Phase 1 data in Q3 2025.
CEO David Angulo said the transfer “enables GSK to initiate regulatory interactions with the FDA to discuss the relaunch of BREXAFEMME for VVC and refractory VVC in the U.S. market.” He added that the milestone and royalty structure will provide a steady stream of revenue that will allow SCYNEXIS to focus on advancing its pipeline rather than on commercialization logistics.
The transfer also reflects GSK’s strategic interest in expanding its infectious‑disease portfolio. By leveraging GSK’s established commercialization capabilities, SCYNEXIS can accelerate the market entry of BREXAFEMME while reallocating resources to research and development, positioning the company for long‑term growth.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.